Overview

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate rexaceract for the treatment of Parkinson’s disease and other neurodegenerative diseases is currently being evaluated in a Phase 1b clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 5 trillion compounds in less than 3 months.